CAMCEVI

This brand name is authorized in Estonia, Croatia, Lithuania, Romania, United States

Active ingredients

The drug CAMCEVI contains one active pharmaceutical ingredient (API):

1 Leuprorelin UNII 8E3C3C493W - LEUPROLIDE MESYLATE

Leuprorelin is inactive when given orally due to poor membrane permeability and an almost complete inactivation by intestinal proteolytic enzymes. Leuprorelin has potent LHRH agonist properties when given during short-term and intermittent therapy, however, when administered in a continuous, nonpulsatile manner, LHRH analogs induce inhibition of gonadotropin secretion and suppression of testicular steroidogenesis. Read about Leuprorelin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CAMCEVI Prolonged-release suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02AE02	Leuprorelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1885035
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094953
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68882001
Country: US	FDA, National Drug Code	Identifier(s): 69448-014